Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.87), $0.01 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $198 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• TDS drops bid for Array Digital Infrastructure minority shares
• Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ